132 related articles for article (PubMed ID: 35360461)
1. Lack of Content Uniformity in MMR Vaccine.
Isaacs JT; Almeter PJ; Henderson BS; Hunter AN; Platt TL; Lodder RA
Contact Context; 2022; 2022():. PubMed ID: 35360461
[TBL] [Abstract][Full Text] [Related]
2. Variability in Content of Piperacillin and Tazobactam Injection.
Isaacs JT; Almeter PJ; Henderson BS; Hunter AN; Platt TL; Lodder RA
Contact Context; 2022; 2022():. PubMed ID: 35506061
[TBL] [Abstract][Full Text] [Related]
3. Potential Process Control Issues with Pemetrexed.
Isaacs JT; Almeter PJ; Henderson BS; Hunter AN; Platt TL; Lodder RA
Contact Context; 2022; 2022():. PubMed ID: 35967958
[TBL] [Abstract][Full Text] [Related]
4. Spectrometric Analysis of Process Variations in Remifentanil.
Isaacs JT; Almeter PJ; Henderson BS; Hunter AN; Platt TL; Lodder RA
Contact Context; 2022; 2022():. PubMed ID: 36187755
[TBL] [Abstract][Full Text] [Related]
5. FTNIR Spectrometry of Micafungin Sodium Quality.
Isaacs JT; Almeter PJ; Henderson BS; Hunter AN; Platt TL; Lodder RA
Contact Context; 2022; 2022():. PubMed ID: 35360460
[TBL] [Abstract][Full Text] [Related]
6. Spectral Intra-Lot and Inter-Lot Variability in Carfilzomib.
Isaacs JT; Almeter PJ; Henderson BS; Hunter AN; Platt TL; Anwar H; Lodder RA
Contact Context; 2023; 2023():. PubMed ID: 37008539
[TBL] [Abstract][Full Text] [Related]
7. Levothyroxine Variations by Process Analytical Technology.
Isaacs JT; Almeter PJ; Henderson BS; Hunter AN; Platt TL; Lodder RA
Contact Context; 2022; 2022():. PubMed ID: 35440917
[TBL] [Abstract][Full Text] [Related]
8. Spectrometric Results of Process Variations in Dacarbazine.
Isaacs JT; Almeter PJ; Henderson BS; Hunter AN; Platt TL; Lodder RA
Contact Context; 2022; 2022():. PubMed ID: 35035310
[TBL] [Abstract][Full Text] [Related]
9. Spectrometric Analysis of Dantrolene Sodium.
Isaacs JT; Almeter PJ; Henderson BS; Hunter AN; Platt TL; McGuire C; Lodder RA
Contact Context; 2023; 2023():. PubMed ID: 37424832
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study.
Klein NP; Abu-Elyazeed R; Povey M; Macias Parra M; Diez-Domingo J; Ahonen A; Korhonen T; Tinoco JC; Weiner L; Marshall GS; Silas PE; Sarpong KO; Ramsey KP; Fling JA; Speicher D; Campos M; Munjal I; Peltier C; Vesikari T; Baccarini C; Caplanusi A; Gillard P; Carryn S; Henry O
J Pediatric Infect Dis Soc; 2020 Apr; 9(2):194-201. PubMed ID: 30849175
[TBL] [Abstract][Full Text] [Related]
11. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children.
Lee CY; Tang RB; Huang FY; Tang H; Huang LM; Bock HL
Int J Infect Dis; 2002 Sep; 6(3):202-9. PubMed ID: 12718836
[TBL] [Abstract][Full Text] [Related]
12. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.
Wellington K; Goa KL
Drugs; 2003; 63(19):2107-26. PubMed ID: 12962524
[TBL] [Abstract][Full Text] [Related]
13. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
[TBL] [Abstract][Full Text] [Related]
14. Vaccines for measles, mumps and rubella in children.
Demicheli V; Rivetti A; Debalini MG; Di Pietrantonj C
Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD004407. PubMed ID: 22336803
[TBL] [Abstract][Full Text] [Related]
15. Two doses of measles mumps rubella (MMR) vaccine.
Kuno-Sakai H; Ozaki K; Kimura M
Acta Paediatr Jpn; 1989 Dec; 31(6):690-7. PubMed ID: 2516395
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and reactogenicity of a new measles, mumps and rubella vaccine when administered as a second dose at 12 y of age.
Gothefors L; Bergström E; Backman M
Scand J Infect Dis; 2001; 33(7):545-9. PubMed ID: 11515768
[TBL] [Abstract][Full Text] [Related]
17. Intra-Lot and Inter-Lot Variability in Cosyntropin.
Almeter PJ; Isaacs JT; Hunter AN; Henderson BS; Lodder RA
Contact Context; 2021; 2021():. PubMed ID: 35035309
[TBL] [Abstract][Full Text] [Related]
18. Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12-15 Months.
Mufson MA; Diaz C; Leonardi M; Harrison CJ; Grogg S; Carbayo A; Carlo-Torres S; JeanFreau R; Quintero-Del-Rio A; Bautista G; Povey M; Da Costa C; Nicholson O; Innis BL
J Pediatric Infect Dis Soc; 2015 Dec; 4(4):339-48. PubMed ID: 26582873
[TBL] [Abstract][Full Text] [Related]
19. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.
Usonis V; Bakasenas V; Kaufhold A; Chitour K; Clemens R
Pediatr Infect Dis J; 1999 Jan; 18(1):42-8. PubMed ID: 9951979
[TBL] [Abstract][Full Text] [Related]
20. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G
Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
